PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.21%
Cash & equivalents declining -13.21% while CRVO's grows 44.81%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-13.21%
Cash + STI yoy 0.5-0.75x CRVO's -21.69%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.76%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-11.17%
0.5-0.75x CRVO's -18.69%. Martin Whitman might see risk if this hampers near-term financial flexibility.
7.73%
Higher PP&E (Net) Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both CRVO and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.08%
Higher Total Non-Current Assets Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-10.65%
0.5-0.75x CRVO's -18.69%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-100.00%
Less than half of CRVO's 898.39%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Similar yoy changes to CRVO's -100.00%. Walter Schloss finds a parallel approach to short-term funding.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half of CRVO's 6.91%. Michael Burry suspects a big gap in pre-sales traction.
1577.51%
Exceeding 1.5x CRVO's 107.98%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-26.01%
Above 1.5x CRVO's -12.05%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-6.06%
50-75% of CRVO's -12.05%. Bruce Berkowitz notes a lower yoy liability increase.
No Data
No Data available this quarter, please select a different quarter.
-3.82%
1.25-1.5x CRVO's -2.81%. Bruce Berkowitz notes stronger reinvestment strategy.
100.00%
Similar yoy to CRVO's 91.17%. Walter Schloss sees parallel comprehensive income changes.
No Data
No Data available this quarter, please select a different quarter.
-13.95%
0.5-0.75x CRVO's -19.48%. Martin Whitman is wary of lagging equity growth vs. competitor.
-10.65%
0.5-0.75x CRVO's -18.69%. Martin Whitman sees underexpansion or possible missed opportunities.
-100.00%
1.25-1.5x CRVO's -75.89%. Bruce Berkowitz checks if robust new investments are prudent.
-4.69%
50-75% of CRVO's -6.91%. Bruce Berkowitz sees relatively smaller yoy debt additions.
13.42%
Less than half of CRVO's -234.31%. David Dodd sees better deleveraging or stronger cash buildup than competitor.